Marcel Rozencweig
President
Your CSV is on the way
We’ve sent your CSV file to email@email.com
Claimed by
owner Add to list
NeoTX
Former names:
Immuno-oncology Drug Development
Stealth Mode
NeoTX
NeoTX Overview
NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful yet safe native antibacterial immune reaction.
The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.
The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.
Cumulative Funding Raised Over Time ($)
Employees Over Time
NeoTX Climate Tech relevance
null
No Data, yet.
Sorry, no content found under this section.
Aug 3, 2022
www.geektime.com
Curing cancer is no small feat: Israel's NeoTX is still up for the challenge
#Expand
Jun 1, 2022
www.prnewswire.com
NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)
#Partners #Acquisition
May 12, 2022
www.prnewswire.com
NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM
#Acquisition
Jan 31, 2022
www.prnewswire.com
NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer
#Management Changes
Aug 3, 2020
www.globenewswire.com
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
#Partners
Companies you might be interested in
Driven by Finder AI
-
Biond BiologicsImmunotherapies for Cancer and Auto-immune Diseases11-50 employees • Funding Stage: C
shared sectors
Are these companies similar? -
ImPact BiotechTargeted Treatment for Selective Tumor Ablation11-50 employees • Funding Stage: Pre-Funding
shared sectors
Also shared
Are these companies similar? -
Hopec PharmaImmunotherapy Treatment for Bladder Cancer1-10 employees • Funding Stage: Seed
shared sectors
Are these companies similar? -
caVos BiotherapeuticsNovel Anti-cancer Drugs1-10 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar?
Primary sector
Total funding
Funding stage
Number of employees
Founded
Related Content
Lists. Maps. Reports
Team Members
MR
AN
RH
SF
Contact Team
Affiliated Organizations
(null)Web & social links
https://neotx.com/
Locations
Israel
Prof. Haim Pekeris Street 2, Rehovot, Israel
Offices Abroad
Photos & videos
(3)No Data, yet.
Sorry, no content found under this section.
NeoTX3
NeoTX2
NeoTX1
NeoTX Business
Sector
Primary:
Health Tech & Life Sciences
Target Customer
Core Technology
Use Cases
(0)Tech Community Involvement
(0)NeoTX Financials
Cumulative Funding Raised Over Time ($)
No Data, yet.
Sorry, no content found under this section.
Public Offerings & Exits
Private Equity Funding
C Round
$45M
Feb 2020
4
Investors
$45M
B Round
$8.8M
Dec 2017
1
Investors
$8.8M
Non-Equity Funding
Mergers and Acquisitions
M&A
Undisclosed
May 2022
Type
Acquisition
Acquired
InterX
Undisclosed
NeoTX Lifecycle
Cumulative Funding Raised Over Time ($)
Timeline
Employees Over Time
News Over Time
No Data, yet.
Sorry, no content found under this section.
M&A
Undisclosed
May 2022
Type
Acquisition
Acquired
InterX
Undisclosed
C Round
$45M
Feb 2020
4
Investors
$45M
B Round
$8.8M
Dec 2017
1
Investors
$8.8M
NeoTX News
News Over Time
No Data, yet.
Sorry, no content found under this section.
News Articles
Aug 3, 2022
www.geektime.com
Curing cancer is no small feat: Israel's NeoTX is still up for the challenge
#Expand
Jun 1, 2022
www.prnewswire.com
NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)
#Partners #Acquisition
May 12, 2022
www.prnewswire.com
NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM
#Acquisition
Jan 31, 2022
www.prnewswire.com
NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer
#Management Changes
Aug 3, 2020
www.globenewswire.com
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
#Partners
Related Content
NeoTX Team
No Data, yet.
Sorry, no content found under this section.
Employees Over Time
Companies you might be interested in
Driven by Finder AI
-
Biond BiologicsImmunotherapies for Cancer and Auto-immune Diseases11-50 employees • Funding Stage: C
shared sectors
Are these companies similar?
-
ImPact BiotechTargeted Treatment for Selective Tumor Ablation11-50 employees • Funding Stage: Pre-Funding
shared sectors
Also shared
Are these companies similar? -
Hopec PharmaImmunotherapy Treatment for Bladder Cancer1-10 employees • Funding Stage: Seed
shared sectors
Are these companies similar?
-
caVos BiotherapeuticsNovel Anti-cancer Drugs1-10 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar?
NeoTX Internal
Create note
Notes
(undefined)
Filter notes
Content Writer
undefined
BI Verification
undefined
Phone Number
undefined
Israel Register ID
undefined
Confidence Score
undefined
Missing Fields
undefined
Profile Creator
undefined
Profile Update
undefined
undefined
Access Comprehensive Financial Analytics
Create a free account to:
- Explore detailed financial analytics.
- Track company growth and size.
- Connect with company team members.
I already have access,
I already have access,